Colorectal cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• TP53 6
• KRAS 57
• PD-1 108
• BRAF 35
• EGFR 32
• PD-L1 26
• PI3K 2
• STAT3 0
• CTNNB1 1
• AKT 0
• RAS 30
• HER2 37
• mTOR 1
• MAPK 1
• VEGF 14
• ERK 0
• STING 0
• NRF2 0
• PPAR 0
• CTLA-4 16
• HIF-1 0
• COX-2 5
• AMPK 0
• JNK 0
• PTEN 1
• YAP 0
• MYC 0
• GPX4 0
• NRAS 8
• IL-6 0
• JAK 0
• MET 7
• PARP 1
• CXCR4 0
• NLRP3 0
• TNF 0
• BCL-2 0
• HSP90 0
• PIK3CA 2
• GLP-1 1
• HDAC 2
• METTL3 0
• MEK 1
• CDK4/6 2
• CD47 1
• BRCA1 1
• FGFR 0
• NTRK 1
• B7-H3 5
• EZH2 0
• FAK 1
• HMGB1 0
• TROP2 4
• MUC1 2
• ATM 2
• IDO1 1
• IL-1 0
• PCSK9 3
• PINK1 0
• SHP2 0

EU-13 is a filter, not a ranking: it only narrows the list.

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

  NCT06365970· Ibrahim Halil Sahin· Updated 3 Feb 2025

  “Per drug sponsor request.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

  NCT02484404· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 131
• Organoids 108
• Mendelian Randomization Analysis 49
• CRISPR-Cas Systems 34
• Gene Expression Profiling 334
• Sequence Analysis, RNA 29
• Whole Genome Sequencing 21
• Exome Sequencing 26
• Proteomics 102
• Metabolomics 92
• Mass Spectrometry 42
• Flow Cytometry 113
• Immunohistochemistry 207
• Liquid Biopsy 36
• Circulating Tumor DNA 119
• Xenograft Model Antitumor Assays 432
• Positron-Emission Tomography 38
• Magnetic Resonance Imaging 195
• Machine Learning 209
• Deep Learning 141
• Cohort Studies 314
• Genome-Wide Association Study 65

• Automated Tissue Classification and Candidate Biomarker Feature Extraction in Mass Spectrometry Imaging Based on Interpretable Deep Learning Algorithm.

  Rapid Commun Mass Spectrom, Nov 2026

• Intraoperative margin assessment in colorectal cancer via AI-enhanced multiphoton microscopy.

  J Biomed Opt, Oct 2026

• FCVGAN: A Novel Generative Framework Integrating Fuzzy C-Means Clustering with Conditional VAE-GAN for Polyp Segmentation.

  Sensors (Basel), Sept 2026

• RareCode: An Unsupervised Deep Learning Framework for Anomaly Detection in Colorectal Cancer Histopathological Images.

  J Vis Exp, Sept 2026

• From cell counts to cellular interactions: Cu-Cyto and the co-localization index as a spatial framework for the tumor immune microenvironment of rectal cancer.

  Int J Clin Oncol, Sept 2026

• Colorectal Lesion diagnosis using transformer and deep learning with multiscale feature interface.

  PLoS One, Sept 2026

• A Vision Transformer- and Radiomics-based Model for Predicting Liver Metastasis-Free Survival in Patients with Rectal Cancer.

  Radiol Imaging Cancer, Sept 2026

• Real-world clinical impact of implementing and updating a deep learning-based automatic contouring system in rectal cancer radiotherapy.

  J Appl Clin Med Phys, Sept 2026

• DNAmBERT: a transformer-based model for non-invasive cancer diagnosis using DNA sequence and methylation data.

  Brief Bioinform, Sept 2026

• A nomogram integrating multi-channel 2.5D twins-SVT deep learning and radiomics for predicting disease-free survival in patients with locally advanced rectal cancer following primary total mesorectal excision.

  Eur J Radiol, Aug 2026

See which targets of this disease your abstract mentions, and go to the people working on them.